Login to Your Account



Pharma: Clinic roundup


Thursday, January 9, 2014
Takeda Pharmaceutical Co. Ltd., of Osaka, Japan, said vedolizumab, a humanized monoclonal antibody antagonizing alpha4beta7 intregrin for treating moderate and severe ulcerative colitis and Crohn’s disease, entered two new Phase III trials in Japan.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription